PubMed Health⌕ Search

Biomedical subjects

J W Holfert

Publications and source records attributed to J W Holfert.

12 recordsLinked to original sources
PubMed1990

Development of a biocompatible hermetically sealed electrical feedthrough.

A new biocompatible hermetically sealed electric wire feedthrough has been developed for use in a totally implantable artificial heart (TAH) and ventricular assist device (VAD). This feedthrough allows electric current to pass through a rigid polyurethane (Isoplast 301, Dow Chemical U.S.A., Midland, MI) housing wall. The implantable housing is exposed externally to tissue and body fluids and is filled with low viscosity silicone oil (decamethyltetrasiloxane) which acts as a hydraulic fluid. The feedthrough prevents fluid transfer which caused early prototype devices to fail. The feedthrough consists of external and internal wires insulated with soft segmented polyurethane (Biomer, Ethicon, Somerville, NJ) and soldered to opposite ends of a conductive pin. The pin and the wire connections are encapsulated in Biomer, forming a leak-free barrier between the housing wall and the wire insulation. The pin soldered between the two wires prevents leakage from between the strands and the insulation.

Animals↗
PubMedDate not supplied

Mechanical failures of the pneumatic Utah-100 and Jarvik total artificial hearts. A comparative study.

Jarvik-5 and Jarvik-7 total artificial hearts (TAHs) and Utah-100 TAHs were fabricated and implanted in calves and sheep. In the Jarvik series, 30.7% had mechanical failures (16.1% catastrophic). In the Utah-100 TAH series, 11.1% had mechanical failures (3.7% catastrophic). Failures were classified as: 1) diaphragm failures; 2) valve-holding ring failures; 3) air-leak failures; and 4) prosthetic valve failures. Marked reduction in mechanical failure for the Utah-100 TAH is attributed to progressive component redesign, material selection, and more stringent quality control criteria.

Animals↗
PubMedDate not supplied

Electrohydraulic ventricular assist device development.

An electrohydraulic ventricular assist device has been developed. An axial flow pump driven by a brushless DC motor provides actuation. Energy is supplied by internal Ni/Cd batteries and by external Ag/Zn batteries, both rechargeable. Electromagnetic induction is used to pass energy through the skin with a transcutaneous energy transfer (TET) system. Physiologic control, battery management, motor commutation, and communication functions are performed by a surface mount internal controller. An infrared data link within the TET coils provides bidirectional communication between the external and internal controllers. A computer model was developed to predict system performance. The dimensions are 180 mm x 116 mm x 40 mm. An in vitro system pumped 5.7 L/min at 10 mmHg inflow and 100 mmHg outflow pressure. The internal battery can provide the projected energy requirements for 40 min after 540 charge/discharge cycles, and the external battery is capable of 4 hr of operation after 150 cycles. The TET system can deliver 60 W of power and exceeds 80% efficiency between 15 and 30 W. The device configuration is based on human cadaver and intraoperative fit trials. The device is being modified for calf implantation by redirecting the blood ports, increasing the output, and incorporating the internal controller in the unified device base.

Animals↗
PubMedDate not supplied

A blood pump with an interatrial shunt for use as an electrohydraulic total artificial heart.

A recently designed blood pump subsystem for the completely implantable electrohydraulic total artificial heart (EHTAH) has been developed and is under evaluation. The subsystem consists of joined left and right ventricles, atrial cuffs with an interatrial shunt (IAS), and two outflow grafts. The ventricles were developed to fit within the pericardial space based on the results of anatomic fit trials. An optimized configuration for animal use, which was adaptable for human use with minimal modification, was identified. The core dimensions of the ventricles with an energy converter are approximately 10 x 11 x 7 cm. Maximum output and stroke volume are 9.2 L/min and 81 ml, respectively. The IAS is used to balance the volumetrically coupled EHTAH, and is made by forming an orifice in the common septum of the left and right atrial cuffs. Performance and durability of the IAS were examined in animal experiments for up to 9 days. The diameter of the IAS was 3.4-5.5 mm, and the left-right atrial pressure difference ranged from 2 to 10 mmHg, with 0.57-1.48 L/min of theoretically calculated shunt flow. No evidence of thrombus formation was found in or around the IAS at autopsy. The entire EHTAH system with a new blood pump is being assembled for long-term animal studies.

Animals↗
PubMedDate not supplied

Animal implantation results with the Utah-100 total artificial heart.

The Utah-100 total artificial heart was designed to have increased reliability over the Jarvik-7 total artificial heart, achieve better fit, and minimize device associated thrombus formation, without decreasing the function. The Utah-100 heart was tested in 28 calves and 3 sheep. The smallest animal at the time of implantation weighted 54 kg. Mean survival duration was 78 days (range, 1-331 days), with 14 animals surviving longer than 60 days. Multiple organ function was maintained satisfactorily with the Utah-100 artificial heart, and mean plasma free hemoglobin values in the calves that survived longer than 100 days were less than 10 mg/dl. Hemorrhage was the main cause of death in animals dying within 30 days after implantation (5/13, 38%); infection was another primary cause of death or termination (4/31, 13%). Deaths due to mechanical failure occurred from valve or diaphragm failure in two cases, yielding a 91% reliability at a 90% confidence level for 60 days' support. No animal died because of driver or other technical failure. Utah-100 hearts showed superior antithrombogenicity in the connector and valve-related areas when compared with the results of the Jarvik-7 heart, which was also fabricated and implanted in our laboratory (p less than 0.01). With these test results, the authors anticipate that the Utah-100 heart will be a safe and effective device for interim use as a bridge to heart transplantation.

Animals↗
PubMedDate not supplied

Preliminary in vitro evaluation of the first neonatal total artificial heart.

A neonatal total artificial heart (TAH), used as a bridging device, can offer circulatory support for patients suffering from otherwise insupportable and inoperable congenital cardiac defects. The choice of the 7.0 ml stroke volume (SV) was based on reported studies on cardiac output (CO) requirements and maximum dimensions of a neonate size TAH. This SV will allow a bridging period of up to 10 weeks in the growing neonate. For in vitro testing purposes, "high-profile" ball valves of in-house design (10-13 mm ID) were used. Redesign of the existing in vitro testing systems, including mock circulation and high-flow blood reservoirs, was required for the smaller device. Mock circulation studies (rates 90-160 BPM, full-fill and ejection modes) showed adequate device performance, with CO values well above the reported marginal output value of 139 ml/kg/min.

Heart Defects, Congenital↗
PubMedDate not supplied

Electrohydraulic ventricular assist device development.

A 64 ml (effective stroke volume) in vitro electrohydraulic ventricular assist device (VAD) prototype has been built. The energy converter is an axial flow pump driven by a brushless direct current (DC) motor. Systole begins as silicone oil is pumped from the volume displacement chamber (VDC) into the ventricle, displacing the flexing diaphragm separating the oil and the blood. In diastole, the motor reverses, providing active filling by pumping oil from the ventricle into the VDC. The surface mount electronic internal controller provides motor commutator, energy management, telemetry, and physiologic control functions. Energy is supplied externally by either a 12 V DC power supply or a 12 V DC rechargeable battery and is transmitted through the skin by a transcutaneous energy transformer (TET). Energy can also be supplied by a 12 V DC rechargeable internal battery. Bidirectional infrared telemetry is used to transmit information between the internal and external controllers.

Blood Pressure↗
PubMedDate not supplied

A total artificial heart for neonates allowing bridging to transplantation.

Since the early 1980s, a rapid increase in successful pediatric heart transplantation has improved the chance of survival for many children suffering from otherwise fatal cardiomyopathies or congenital cardiac defects. During the last 5 years, heart transplantation in neonates and infants (0-28 days and 1-12 months, respectively) has been the most rapidly growing area within the pediatric patient population. No adequate mechanical circulatory support system, designed to be used as a bridge to transplantation, is available for many of these pediatric patients. Neonates are the smallest candidates to potentially benefit from heart transplantation, and their often acute need for either heart transplantation or temporary circulatory support indicates that any new development of a pediatric bridging device should focus on this youngest group. Subsequently, such a device may be modified to any weight or age group. An innovative total artificial heart design was developed in an attempt to meet the anatomic and physiologic requirements of neonates and infants. This report discusses the rapidly growing pediatric heart transplantation patient population, as well as an innovative total artificial heart design.

Blood Pressure↗
PubMedDate not supplied

Design mediated thrombus reduction in the Utah-100 total artificial heart.

The Utah-100 total artificial heart was initially designed and tested in 1983. General design goals, including improved fit for human application, improved reliability, and elimination of thrombus formation, were identified as improvements over the clinically used Jarvik-7 artificial heart, previously developed at the Institute for Biomedical Engineering, University of Utah. Specific design goals included 1) elimination of connector and valve-associated thrombus formation and 2) elimination of gross mineralization, thrombus formation, and creases on the blood-pumping diaphragm of the device. Explant retrieval results from 29 calves and sheep implanted with the Jarvik-7 artificial heart were compared with results from 25 calves and sheep implanted with the Utah-100 artificial heart. Macroscopic thrombus formation was found in 44% of the connectors of the Jarvik-7 artificial-hearts, compared with 2% (p less than or equal to 0.01) in animals with the Utah-100 artificial heart. Subvalvular and supravalvular thrombi were observed in 33% of the valves in the Jarvik-7 artificial heart and 10% (p less than or equal to 0.01) of the valves in the Utah-100 artificial heart. Mineralization of the pumping diaphragm was observed in 12% of the animals implanted with the Jarvik-7 artificial heart and in 4% of the animals with the Utah-100 diaphragms. Thrombus formation in the diaphragm-housing interface occurred in 2% of Jarvik-7 ventricles and in 6% of the Utah-100 ventricles. There were no identifiable diaphragm creases in the Utah-100 diaphragms, but a 10% incidence was found in Jarvik-7 devices. These results validate substantial progress toward improved design and fabrication methods in the Utah-100 total artificial heart.

Animals↗
PubMedDate not supplied

In vitro analysis of an atrial shunt in balancing an electrohydraulic total artificial heart.

In vitro tests were performed to evaluate the use of an interatrial shunt in balancing a dual energy converter, actively filled, volumetrically coupled, electrohydraulic total artificial heart. The in vitro atrial shunt was comprised of a 8 mm (PTFE) Teflon graft placed between the left and the right atrium. Other features under study were 1) cardiac output (CO) response to preload, 2) CO relationship to mean aortic pressure, and 3) balance of ventricular outputs. The tests were performed by varying the right filling pressure and monitoring ventricular output and inflow/outflow pressures. Effects of changes in afterload were simulated by varying the (AoP) pressure from 80 mmHg to 120 mmHg, and the (PAP) pressure from 15 mmHg to 40 mmHg. The test results indicated a rise in CO from 4 L/min to 9 L/min, with a change in mean right atrial pressure from 0 mmHg to 12 mmHg. No significant difference in CO was found as afterload pressures were varied. The interatrial shunt (IAS) was effective in establishing ventricular balance over a wide range of preload and afterload conditions, and a mean positive flow from left to right was maintained in the atrial shunt, even at conditions simulating an extreme left-right imbalance.

Blood Flow Velocity↗
PubMedDate not supplied

In vivo long-term evaluation of the Utah electrohydraulic total artificial heart.

An electrohydraulic total artificial heart (EHTAH) has been developed and evaluated by long-term in vivo studies. The EHTAH is composed of blood pumps with an interatrial shunt (IAS), an energy converter, and electronics. The EHTAH with external electronics was implanted in four calves weighing from 81-90 kg. Two animals died on the 1st and 5th post operative days, the third animal survived for 32 days, and the fourth for 159 days. The IAS was free of thrombus at autopsy in all animals. The longest surviving animal increased in size from a pre operative weight of 81 kg to 134 kg on day 144. Cardiac output ranged from 9.3 to 10.5 L/min, whereas right and left atrial pressures increased with the calf's growth from 4-10 to 16-20 mmHg and from 8-14 to 18-22 mmHg, respectively. The animal favorably tolerated up to 3.4 km/hr of treadmill exercise, both hemodynamically and metabolically. The elevation of atrial pressures during treadmill exercise was significantly alleviated by employing an automatic control mode. It is concluded that the device has the potential to be a totally implantable system for permanent use.

Animals↗